Vazegepant (BHV-3500) hydrochloride 是一种高度亲和性 CGRP 受体拮抗剂 (hCGRP Ki=0.023 nM)。Vazegepant hydrochloride 是第一种用于偏头痛的鼻用 gepant。Vazegepant hydrochloride 可能有助于有效管理 COVID-19 相关肺部炎症。
Vazegepant (BHV-3500) hydrochloride is a highly affinity CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine. Vazegepant hydrochloride may be helpful in effective management of COVID-19 associated pulmonary inflammation[1][2][3].
[1]. Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. Curr Opin Neurol. 2020;33(3):309-315.
[2]. Mehta PP, et al. Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications. Am J Med Sci. 2021;361(5):557-566.
[3]. Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. Curr Opin Neurol. 2020;33(3):309-315.
动态评分
0.0